⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27271920 | 1.00 | — | — | |
| SCHEMBL27271914 | 1.00 | — | — | |
| SCHEMBL22778538 | 1.00 | — | — | |
| SCHEMBL21653690 | 0.85 | — | — | |
| SCHEMBL15744055 | 0.84 | — | — | |
| SCHEMBL3004250 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL21268628 | 0.80 | — | — | |
| SCHEMBL19750771 | 0.79 | — | — | |
| SCHEMBL23134489 | 0.79 | LMNA (0.38) | — | |
| SCHEMBL16474016 | 0.74 | SLC22A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| EP-3310775-B1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma AG (DE) | 2020-04-01 | — | — | EP | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2781520-B1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| EP-2781520-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014127816-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2280975-B1 | 7H-INDOLO[2,1-A][2]BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2009137454-A1 | 7H-INDOLO[2,1-A] [2] BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-5624941-A | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-04-29 | — | — | US | disclosed |